Table 1.
Imaging results for each patient in the study
| Patient number/sex/age, years | Diagnosis | Changes in overall alkaline phosphatase levels/bone alkaline phosphatase levels, baseline→follow-up (IU/L) | Lesions (n), baseline→follow-up/location of lesions (new location(s) | Number of 223RaCl2cycles/cumulative activity |
||
| Bone scintigraphy | Na18F PET/CT (NAFCIST) | 18F-FDG PET/CT (PERCIST) | ||||
| 1/M/71 | Metastatic fibroblastic osteosarcoma | 102→120/9.8→10 | 3→3↑/bone (T, P, E) | 8→11 (42.4→66.5)/bone (+V)(soft tissue [P]) | 9→12 (30.4→32.4)/bone, soft tissue | 3/12.66 MBq |
| 2/M/15 | Metastatic osteoblastic osteosarcoma | 78→80/19→21 | 4→4↑/bone (V, T, P) | 1→2 (3.6→9.2)/bone | 3/13.71 MBq | |
| 3/M/20 | Metastatic chondroblastic osteosarcoma | 101→281/26→93 | 3→9↑/bone (V, T) | 9→14 (115.1→211.6)/bone (+C, P, E) (soft tissue [V]) | 6→>10↑ (24.0→46.6)/bone, soft tissue (lung) | 2/7.24 MBq |
| 4/M/29 | Metastatic osteoblastic osteosarcoma | 339→130/86→28 | 9→9↑/bone (C, P), soft tissue (T), lung | 12→14 (236.9→117.2)/bone, soft tissue, lung, brain | 10→10↑ (51.4→31.9)/bone, soft tissue, lung | 3/13.44 MBq |
| 5/M/18 | Recurrent osteosarcoma | 188 →258/46→69 | 3→5↑/bone (V, P) | 4→6 (235.4→135.5)/bone, soft tissue, lung | 6→8 (28.1→29.3)/bone, soft tissue, lung | 2/11.27 MBq |
| 6/F/46 | Giant cell tumour | 93→108/8.1→9.3 | >30→>30 NC/bone (C, V, T, P, E), soft tissue, lung | >50 (152.3)*/bone, soft tissue, lung, liver | >40→>60 (56.5→80.7)/bone, soft tissue, lung, liver | 3/19.00 MBq |
| 7/M/15 | Metastatic osteosarcoma | 185→282/70→110 | 5→8↑/bone (V, T, P, E) (soft tissue) | 5→7 (11.5→14.7)/bone, soft tissue | 2/10.64 MBq | |
| 8/M/18 | Metastatic osteoblastic osteosarcoma | 84→80/24→16 | 1→4↑/bone (V, T) | 6→7 (62.0→71.2)/bone (+C) | 2→5 (9.3→20.2)/bone (soft tissue) | 2/13.84 MBq |
| 9/M/16 | Metastatic osteoblastic osteosarcoma | 233→992/75→306 | 5→10↑/lung | >10→>50 (118.4→199.3)/lung (brain) | 2/15.30 MBq | |
| 10/M/24 | Metastatic osteoblastic osteosarcoma | 148/50 | 1→3↑/bone (C, V, P) | 5→16 (36.1→36.9)/bone, soft tissue, lung | 1/6.84 MBq | |
| 11/M/15 | Metastatic osteoblastic osteosarcoma | 256/92 | 2→2↑/bone (P, E), soft tissue | 2→2↑ (76.3→112.3)/bone, soft tissue | 1/7.14 MBq | |
| 12/M/58 | Metastatic osteoblastic osteosarcoma | 115→98/22→19 | 2→2NC→ 2↑†/bone (T), lung | 3→5↓→6↓† (381→302→429)/bone, soft tissue, lung | 3 (21.8)*/bone, soft tissue, lung | 6/57.81 MBq |
| 13/M/22 | Metastatic high-grade osteosarcoma | 1147→2098/348→599 | 6→6↑/lung, soft tissue (T) | 17→24 (120.4→125.6)/soft tissue, lung (bone [+T]) | 2/9.36 MBq | |
| 14/M/63 | Metastatic fibroblastic osteosarcoma | 185→75/43→8.7 | 3→3↓→3↓†/bone (V, P), soft tissue | 5→5→5† (247→99→81.5)/bone, soft tissue | 6/50.33 MBq | |
| 15/F/17 | Metastatic chondroblastic osteosarcoma | 192→149/66→53 | 1→4↑/bone (V, P) | 1→6 (15.3→39.7)/bone (soft tissue) | 3/25.21 MBq | |
| 16/M/26 | Metastatic chondroblastic osteosarcoma | 149→53/34→10 | 2→2 NC/bone (E), soft tissue | 3→2 (98.9→49.9)/bone, soft tissue | 3/16.93 MBq | |
| 17/M/15 | Metastatic osteoblastic osteosarcoma | 6971→770/>2000 | >10→>70↑/bone (C, V, T, P, E) (lung) | >10→>150 (152.8→302.9)/bone (soft tissue, lung) | 2/13.23 MBq | |
| 18/F/43 | Metastatic fibroblastic osteosarcoma | 116→80/32→18 | 5→5 NC/soft tissue (bone [C, T]) | 8→8↑ (259.7→215.9)/soft tissue (bone [+V]) | 6 (28.5)**/bone, soft tissue | 3/24.74 MBq |
*Study performed at baseline only.
†Studies were performed three times: baseline, after 3 cycles, and after 6 cycles.
↓, visual decrease (response); ↑, visual increase (progression); C, cranium; E, extremity; F, female; 18F-FDG, fluorine-18-fluorodeoxyglucose; M, male; NAFCIST, Na18F PET response Criteria in Solid Tumors; Na18F, sodium fluoride-18; P, pelvic; PERCIST, PET Response Criteria in Solid Tumors; PET, positron emission tomography; T, thoracic; V, vetebrae.